CATalyst Council Releases Second Edition of “Puppocalypse, Kitten Craze” Report, Confirming Its Veterinary Visit Forecast with Q2 2026 Data

CATalyst Council released the second edition of its pet-demographics forecast, incorporating second-quarter 2026 veterinary visit data and new research. The original June white paper projected combined U.S. clinical visit growth of −2% to 0% through 2031, well below industry expectations of 2% to 3%. The update suggests expectations for U.S. veterinary utilization remain subdued, implying softer demand outlook for the near-to-medium term.

Analysis

This is more of a valuation/data-input risk than an immediate earnings shock. The market will likely ignore the headline until it shows up in management commentary, but if visit growth is structurally lower, the first-order losers are the picks-and-shovels names with the highest revenue sensitivity to clinic throughput: diagnostics, consumables, and procedure-driven products. That argues for closer scrutiny of IDEXX and, to a lesser extent, Zoetis, where recurring spend can cushion the hit but volume assumptions matter for mid-teens multiple support.

The second-order effect is margin pressure at the clinic level. If traffic slows while labor stays sticky, independents and lower-end chains absorb the pain first, which can accelerate consolidation into better-capitalized operators and shift share toward value-oriented care, tele-triage, and pharmacy/OTC substitution. That creates a potential relative tailwind for channels that monetize the pet relationship outside the exam room, but only if they can capture spend that would otherwise have been a vet visit.

Contrarian take: the consensus may be over-anchored to pet counts instead of spend per pet. Aging pets, higher acuity, and inflation-driven price increases can keep dollar growth positive even with flat or slightly negative visit counts, so this is not a clean short unless the data starts pulling down guidance. The key falsifier is any visible deceleration in clinic throughput or consumables growth over the next 1-2 quarters; absent that, this remains a monitoring item rather than a high-conviction trade.

Key Decisions for Investors

• Watchlist: reduce exposure to IDEXX (IDXX) on any rally if upcoming guidance implies low-single-digit visit growth assumptions; thesis only works if consumables/test volume growth decelerates for 1-2 quarters.
• Relative-value idea: long ZTS / short IDXX into earnings if clinic-visit data stays weak, on the view that Zoetis can offset volume softness with price and broader product mix better than diagnostics-heavy peers.
• Speculative pair: long CHWY vs. short a vet-traffic proxy only if management evidence shows spend migrating to pharmacy/OTC and home-delivery rather than clinic utilization; otherwise stay out.
• No-action flag: do not short the space outright until a second corroborating dataset confirms lower visit counts; the near-term risk is that pet aging and higher acuity offset the volume slowdown.